US FDA and PhRMA may be headed for showdown over use of foreign reference product bridging studies; PhRMA says that relying on sponsor’s non-public information to waive bridging studies would violate firm’s commercial confidential information, while FDA Commissioner Gottlieb sees ‘public health prerogative’ in considering whether data-sharing agreements with foreign regulators could help eliminate need for unnecessary studies.
The US FDA and the innovator biopharmaceutical industry may be headed for a showdown over the use of foreign reference biologics in biosimilar development programs, pitting what the agency views as a public health issue against industry’s protection of its trade secrets.
The agency is considering whether bridging studies are necessary to establish that US-licensed and foreign-licensed reference biologics are the same...